Tafalgie Therapeutics to benefit from the EIC Accelerator Program

We are proud to announce that Tafalgie Therapeutics is one of only 47[JS1]  European companies (12 of which are French) to have been selected in the November 2023 call for proposals for the European Innovation Council (EIC) “Accelerator” program, which rewards companies displaying excellence in the deployment of radical and [JS2] paradigm-changing innovations.

The EIC Accelerator will enable Tafalgie, a biotech startup based in Marseille, to accelerate the development of its new generation of pain-relieving peptides as an alternative to opioids for the treatment of acute and chronic pain.

The next step is to launch clinical trials and demonstrate efficacy in humans.

Visit our contact page